Market access planning and the GTN roadmap

Timothy Bonn (Moderator) , Senior Director of Gross-to-Net at Breakaway Technologies;
Rohit Gupta, Global Revenue Finance at Seagen;
Mark Lapre, Controller at Karuna Therapeutics, Inc.;
Gina Tracey, Senior Director, Accounting at Alnylam

Market access planning and the GTN roadmap

Click to play video

Forecasting and accrual management
Tracking evolution throughout launch
Auditing preparations throughout process

Tim Bonn earned a Ph. D. in Physical Chemistry from the University of Pennsylvania and then pursued a career in consulting and professional services. Since joining Breakaway Technologies in 2004, he’s developed an extensive data and analytics background and currently leads their GTN practice. Tim works with clients to understand their processes and data to design and build solutions that solve real business problems. He has built his reputation by delivering enterprise solutions that ensure client success.

Rohit Gupta is a finance leader and pharmaceutical/biotech executive. Over last 15 years, he has held roles in Finance and Commercial with various multi-national companies. At Seagen, he leads the Global Revenue Finance function including Gross to Net Reporting. Rohit’s experience spans across corporate finance, strategy & commercial. He has led various finance transformation & system projects and supported the launch of several global brands across different markets. Rohit is a CPA and has an MBA in finance from Gonzaga School of Business.

Mark Lapre is currently the Controller at Karuna Therapeutics, Inc., and joined the company in May 2019 prior to its IPO. Since then, the company has been through multiple capital raises and significant growth and is currently working towards commercialization for its lead product candidate, KarXT, for the treatment of acute psychosis in adults with schizophrenia. Mark’s prior experience includes approximately eleven years in public accounting at Deloitte and RSM.

Gina Tracey is currently a Senior Director of Accounting at Alnylam Pharmaceuticals, Inc. and has been at Alnylam for over four years. She provides technical accounting and operational finance support across all aspects of global product revenue, collaboration revenue and partner programs, global inventory and cost of goods sold, and general manufacturing. Prior to Alnylam, Gina was an audit senior manager at EY, most recently based in the BioScience Hub at Kendall Square in Cambridge, MA. She spent over fourteen years in public accounting, with a focus on working with publicly-traded and privately-owned companies in the life science sectors including biotech, diagnostic and medical devices. Gina holds a CPA license in Massachusetts, a Masters in Accountancy from the University of Virginia, and a BA in Economics from Cornell University.